$2.2M Grant Aims to Move M102, Potential ALS Therapy, Into Trials

$2.2M Grant Aims to Move M102, Potential ALS Therapy, Into Trials

284470

$2.2M Grant Aims to Move M102, Potential ALS Therapy, Into Trials

Work into moving M102, an investigative treatment for amyotrophic lateral sclerosis (ALS), into testing in people has been given a boost by a £1.6 million research grant awarded to Aclipse Therapeutics and the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the U.K. The award, worth roughly $2.2 million, was given by the U.K.’s Medical Research Council (MRC), and adds to a recent $700,000 grant from FightMND, a nonprofit organization in Australia that…

You must be logged in to read/download the full post.